Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Feb 24.
Published in final edited form as: Mol Biosyst. 2012 Oct 5;9(1):10–17. doi: 10.1039/c2mb25088h

Learning the molecular mechanisms of the reprogramming factors: let’s start from microRNAs

Chao-Shun Yang 1, Tariq M Rana 1,*
PMCID: PMC3933261  NIHMSID: NIHMS549440  PMID: 23037570

Abstract

Induced reprogramming of somatic cells has had a great impact on stem cell research, and the reprogramming technologies have evolved from four transgenic factors (Oct4, Sox2, Klf4, and c-Myc; OSKM) to just a few microRNAs (mainly miR-290/302 seed family). Despite these advances, the molecular events occurring during various stages of reprogramming remain largely unknown. Here, we concisely review current knowledge of miRNA regulation from the initiation phase of OSKM-induced reprogramming, through the transitional stage, to final maturation. At the start of reprogramming, the microRNAs miR-21, miR-29a, let-7a, and miR-34 act as guards to secure the somatic identity and genomic integrity of the cell of origin. As reprogramming proceeds, miR-155, miR-10b, miR-205, and miR-429 modulate the epithelial-mesenchymal/mesenchymal-epithelial transition (EMT/MET), which is a critical step towards transformed pluripotent status. Finally, the pluripotency regulatory network is secured in the iPSCs and fine-tuned by a group of miRNAs belonging to the miR-290/302 seed family. Among the four reprogramming factors, c-Myc plays the dominant role in regulating the miRNAs under reprogramming-specific conditions. Accumulating evidence suggests that the reprogramming efficiency can be improved by either blocking barrier miRNAs or introducing helper miRNAs. Intriguingly, induced pluripotency can be obtained by introducing a single miR-302 cluster, although the supportive molecular mechanism is still lacking. In the near future, we may be able to realize the broad potential of miRNAs in the stem cell field, such as altering cell identities with high efficiency through the transient introduction of tissue-specific miRNAs.

Induced reprogramming overview

The new era of reprogramming was initiated by the ectopic expression of four transcription factors in somatic cells, first demonstrated in mouse cells1 and later in human cells2-6, which have the capacity to differentiate into different cell lineages. Using retroviral or lentiviral systems, these four factors, Oct4, Sox2, Klf4/Lin28, and c-Myc/Nanog (also referred to as OSKM or OSLN) can be easily introduced into somatic cells to induce reprogramming to an embryonic stem (ES) cell-like pluripotent state. The induced pluripotent stem cells (iPSCs) generated by this breakthrough technology have provided a valuable alternative resource to human embryonic stem cells7. However, the low efficiency of reprogramming and concerns of genetic modification by the transgenes remain major hurdles in the therapeutic application of iPSCs2, 4, 7, 8. In recent years, substantial progress has been made in improving reprogramming efficiency and in substituting select transcription factors8-11. A few reports have also revealed the great promise of inducing reprogramming with only mRNAs or microRNAs (miRNAs)12-16. Although many windows have been opened to improve the efficiency of reprogramming and to minimize transgenic integrations into the genome, we have only just begun to understand the molecular mechanisms that control reprogramming beyond the four factors. Many studies have shown that reprogramming can be defined and achieved as a step-wise process17-19. Furthermore, several genes and proteins have been identified that have greatly impacted reprogramming efficiency, such as PTGS220, Ink4a/ARF, p53/p2121-26, TGF-□27, 28, and miRNAs29-37.

MicroRNAs are ~22 nucleotide small non-coding RNAs that are highly conserved among species38, 39. They contain short sequences in the 5′ end (“seed” regions) that direct target gene recognition of miRNA-loaded processing complexes, RISCs (RNA-induced Silencing Complexes) 40. In mammals, miRNAs act as post-transcriptional regulators to reduce translation of target genes by either destabilizing mRNAs or blocking their translation. miRNAs have been shown to play critical roles in various physiological processes, including embryogenesis41-43 and tumorigenesis44-48. In addition, numerous reports have shown that miRNAs play significant roles in somatic cell reprogramming to iPSC29-35, 49. The progress and expectations of induced reprogramming technology have been recently described in numerous review articles8-10, 50-57. Several reviews42, 43, 58-64 also address the improvement of reprogramming methods by introducing miRNAs upon induced reprogramming. However, intrinsic roles of miRNAs, which are regulated by OSKM at each stage of reprogramming process, have not been addressed. In this review, we discuss the molecular mechanisms of reprogramming from this unique viewpoint, focusing on the effects of the reprogramming factors on endogenous miRNA regulation and the regulatory networks of these miRNAs during iPSC induction.

Reprogramming is a stochastic but step-wise event

Reprogramming is induced by ectopic expression in somatic cells of the four reprogramming factors that drive the cells to de-differentiate and achieve a state of pluripotency. An increasing body of evidence shows that it is a generally stochastic manner65-67 but is able to achieve step-wise transition during reprogramming17-19, 65. The OSKM reprogramming factors bind their targets in a coordinated fashion19 to initiate the first step of reprogramming, the transcriptional and epigenetic changes19, 68. Furthermore, it has been suggested that OSKM may assemble an inhibitory circuit against somatic identity prior to building up the transcriptional network of pluripotency in the later stages of the transition19, 68. This observation is supported by other reports showing that a number of barriers need to be overcome to reach the next steps in the transition9, 10.

c-Myc plays a key role in establishing the early transition stage

The cellular phenotypes associated with the reprogramming transitions have been reported in recent studies69, 70, but a clear picture of the detailed molecular events driving the transitions is still lacking. Among the four reprogramming factors, c-Myc has been shown to play the dominant role in initiating the early transitional stage19, 68. Expression of c-Myc alone can downregulate the expression of fibroblast-specific genes and induce the molecular context of the embryonic status within 3 days of transduction19. In addition to regulating the expression of hundreds of genes, as shown in previous reports19, 71, c-Myc regulates numerous miRNAs to promote tumorigenesis72-75 and to maintain pluripotency in ES cells76-79. Recently, we demonstrated that c-Myc disrupts the fibroblastic network by inhibiting the mouse embryonic fibroblast (MEF)-enriched miRNAs, miR-21 and miR-29a (Figure 1), to lower the threshold for reprogramming29. Thus, c-Myc establishes the early molecular context of reprogramming, not only by directly interacting with promoter regions of target genes, but also by exerting inhibitory effects on somatic networks by regulating miRNAs.

Figure 1. MicroRNAs play important roles to support reprogramming progress.

Figure 1

A. MicroRNAs in the initial step of reprogramming.

c-Myc has been shown to disrupt the molecular networks of somatic cells to promote the initiation of reprogramming. c-Myc is also the main regulator of miRNA expression early in reprogramming with miR-21 and miR-29a being the main targets of c-Myc at this stage. Let-7 is repressed by c-Myc through Lin-28b-mediated regulation, but this is not detected during early reprogramming. c-Myc also induces the oncogenic stress response by activating p53/miR-34.

B. MicroRNAs in mesenchymal-to-epithelial transition (MET) of reprogramming.

miR-10b and miR-155 promote mesenchymal-like properties, while miR-205 and the miR-200 family (miR-429) promote epithelial-like characteristics. c-Myc coordinates with Klf4, to induce miR-429 upon reprogramming, which accelerates the transition step. miR-290/302 seed family, miR-302 cluster and miR-106b cluster, have been shown to enhance epithelial properties.

C. MicroRNAs in late stage of reprogramming.

In this last step of iPSC maturation, the ES-specific molecular signatures are reactivated, including ES-specific miRNAs, miR-290, and miR-302 clusters. c-Myc plays major roles in inducing miR-290 and miR-302 clusters. miR-290, miR-302, and other miR-290/302 seed family miRNAs also play important roles to restore the ESC properties.

The MEF-enriched miRNAs, miR-21, miR-29a, and let-7, act as barriers to the initial stage of reprogramming

We previously demonstrated that the miRNA expression profile changes dramatically upon OSKM introduction into MEFs, with c-Myc playing the dominant regulatory role in this process29. Furthermore, we have shown that c-Myc decreases the expression of MEF-enriched miRNAs, such as miR-21 and miR-29a (Figure 1). c-Myc transcriptionally suppresses miR-29 expression by binding to its promoter80, while the molecular mechanism by which c-Myc regulates miR-21 expression is still unclear. miR-21 positively regulates the TGF□181 and MAP kinase82 pathways, which have been shown to act as roadblocks to reprogramming27, 28, 31, 34, 69, 83-86. miR-29a has been shown to indirectly induce p53 protein levels by post-transcriptionally inhibiting CDC42 and p85□87. Consistent with these observations, depleting miR-21 or miR-29a dramatically (2 to 3 fold) increases reprogramming efficiency, suggesting that MEF-enriched miRNAs act as barriers to reprogramming29. We also showed that miR-21 and miR-29a modulate reprogramming by regulating phosphorylation of ERK1/2 by 45~60% through Spry1 protein expression. In addition, depletion of miR-21 and miR-29a downregulates p53 protein levels by 25~40% through elevation of CDC42/p85□ expression, which consequently enhances reprogramming efficiency. These data provide evidence for new regulatory networks during reprogramming involving c-Myc, miR-21, and miR-29a.

Another abundant miRNA in MEFs, let-7 (Figure 1), has been shown to act as a barrier to reprogramming, since depleting let-7 enhanced the reprogramming efficiency by 4.3 fold with only the OSK reprogramming factors32. Ectopic expression of c-Myc reduces let-7a expression in MEFs during reprogramming, although to a relatively modest degree29. It has been reported that c-Myc represses let-7 through Lin-28b transactivation75; however, Lin-28b mRNA is undetectable during the early stage of reprogramming29, suggesting other indirect mechanisms may be involved. The let-7 family may exert negative effects on reprogramming, because they are known to repress numerous pluripotent regulators, including Myc, Hmga2, Lin-28, and Sall432, 88-91. To summarize, the MEF-enriched miRNAs, miR-21, miR-29a, and let-7a modulate various pathways to antagonize the reprogramming process. Furthermore, c-Myc has an intrinsic ability to initiate the reprogramming transition, not only by targeting the promoter regions of numerous genes, but also by inhibiting MEF-enriched miRNAs in the initial stage of reprogramming.

p53-regulated miRNA miR-34 and miR145 play important roles in reprogramming

The introduction of reprogramming factors into somatic cells initiates the cellular stress response to viral infection and oncogenes. Among the stress response molecules, transformation-related protein 53 (Trp53 or p53) plays a critical role as a gate-keeper to ensure that only cells with genomic integrity will survive to reach the pluripotent status, while stochastic nuclear reprogramming is induced21-26. miR-34 (Figure 1) has been identified as a downstream target of p53 and contributes significantly to p53-mediated cell cycle arrest and apoptosis92-94. miR-34a deficiency in murine somatic cells improves the efficiency (> 4 fold) and kinetics (by two days) of reprogramming95. Consistent with this observation, p53-induced miR-34a/b/c act as negative regulators of reprogramming, in part through the repression of pluripotency genes such as Lin28a96, Nanog, Sox2, N-Myc95, and c-Myc97.

After initiation of reprogramming, mesenchymal-to-epithelial transition (MET) is the next step towards pluripotency69, 70. Approximately 5 days after OSKM induction, transformed cells undergo dramatic morphological changes from mesenchymal-like (polarized and mono-adherent) to epithelial-like (densely packed) cells. MET is critical for somatic cells to complete the first step of de-differentiation. Interestingly, miR-34a/b/c have been shown to compromise Snail1-dependent EMT (the reverse transition to MET) in cancer cells by targeting the 3’ untranslated region (UTR) of Snail198, while Snail1 and ZEB1 impose a negative feedback loop on miR-34a/b/c by binding the E-boxes of the miR-34a/b/c promoters97. miR-34a also decreases other EMT factors, such as □-catenin, LEF1, Axin298, Slug, and ZEB197, and ectopic expression of miR-34a also prevents TGF-□□induced EMT97. Therefore, short-term introduction of miR-34a/b/c may suppress the EMT in the early reprogramming process, while reprogramming factors coordinately affect MET to de-differentiate somatic cells. Since miR-34 modulate various functional pathways, miR-34 may play dual roles to secure cell integrity and promote MET in the cell-context-dependent manner.

miR-145, suggested to be the direct target of p5396, plays critical roles to direct differentiation of ES cells99. miR-145 has been reported to downregulate Sox2100, Klf496, and Oct4 to promote mesoderm and ectoderm differentiation in ES cells99. Furthermore, miR-145 promoter region is bound and repressed by Oct4 in ES cells99, suggesting Oct4 may lift the suppression of endogenous OSK by miR-145 during reprogramming. However, regulatory networks of miR-145 during reprogramming need to be vigorously interrogated, since this hasn’t been tested during the process of reprogramming.

EMT/MET-associated miRNAs, miR-155, miR-10b, miR-205, and miR-429 play important roles in modulating the transitional stage of reprogramming

During the MET stage of reprogramming (Figure 1), pro-mesenchymal miRNAs miR-10b101 and miR-155102 decrease69, and pro-epithelial miRNAs miR-205103, 104 and miR-429 (miR-200 family)49, 105-107 increase69, 70. miR-10b promotes EMT in cancer metastases by targeting homeobox D10101, and miR-10b antagomirs suppress metastases in vivo108. miR-155 plays an important role in TGF-□–induced EMT by targeting RhoA102, one of the key factors maintaining junction formation and stabilization109. However, a recent report showed that miR-155 may have dual functions in modulating EMT depending on the microenvironment of the tumor110, suggesting that the functions of miRNAs are cell and/or tissue context-dependent.

Conversely, the miR-200 family and miR-205 have been shown to positively regulate MET by targeting ZEB1 and ZEB2107, 111-113, while ZEB1 reciprocally represses the miR-200 family105, 106. In addition, bone morphogenetic protein (BMP), which is required for efficient reprogramming with OSKM, promotes MET and also induces expression of miR-205 and the miR-200 family during OSKM-induced reprogramming70. Introduction of miR-200b/c mimics synergize with OSKM to promote more efficient reprogramming70. Notably, c-Myc (Figure 1) may boost reprogramming efficiency by directly inducing expression of the miR-200 family (miR-200, miR-141, and miR-429), and possibly coordinating with Klf4 to initiate MET69, 114.

The miR-290/302 seed family plays significant roles during the programming progress

It has been shown that microRNAs maintain the murine ES property by promoting the G1-S transition of the cell cycle and that aberrant miRNA biogenesis impairs proliferation of ES cells, which accumulate in the G1 phase115-117. The key miRNAs for these functions are the miR-290 and miR-302 clusters, which are the most abundant miRNAs (Table 1) in mouse and human ES cells respectively118-120. These two clusters have almost identical seed regions (miR-290/302 seed family; also see Table 2), suggesting they have highly similar target and/or regulatory networks. In human ES cells, the miR-302 cluster is regulated by Oct4/Sox2 to post-transcriptionally modulate cyclin D1, a key regulator of cell cycle progression121, 122. The miR-290/302 seed family modulates cell cycle progression by targeting diverse regulators of the cell cycle, including p21 and other inhibitors of the cyclin E/Cdk2 pathway115. Numerous targets of the miR-302 cluster were uncovered using the photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation method (PAR-CLIP); these included modulation of BMP signaling through suppression of Tob2, Dazap2, and Slain130. miR-302a is known to target Lefty1/2, which is an agonist of the TGF-□/Nodal signaling pathway in embryogenesis123. In mouse ES cells, the miR-290 family controls de novo methylation through Rbl2-dependent regulation of DNA methyltransferase (Dnmts)124, 125. Based on these findings, it appears that the main function of the miR-290/302 seed family is to shorten the G1 phase of the cell cycle to support self-renewal, and to secure the epigenetic status that maintains the pluripotency of ES cells.

Table 1.

Enriched miRNAs in human ES and/or iPS cells relative to IMR90 fibroblasts136

Both in ES and iPS cells Only in ES
cells
hsa-miR-17 hsa-miR-205 hsa-miR-96
hsa-miR-18a hsa-miR-
302a
hsa-miR-222*
hsa-miR-18b hsa-miR-
302a*
hsa-miR-371-5p
hsa-miR-19a hsa-miR-
302b
hsa-miR-372
hsa-miR-19b hsa-miR-
302b*
hsa-miR-373
hsa-miR-20a hsa-miR-
302c
hsa-miR-512-3p
hsa-miR-20b hsa-miR-
302c*
hsa-miR-515-5p
hsa-miR-20b* hsa-miR-
302d
hsa-miR-516a-5p
hsa-miR-25 hsa-miR-
302d*
hsa-miR-516b
hsa-miR-30e hsa-miR-363 hsa-miR-518b
hsa-miR-92a hsa-miR-363* hsa-miR-518d-
5p
hsa-miR-92b hsa-miR-421 hsa-miR-518e*
hsa-miR-93 hsa-miR-486-
5p
hsa-miR-518f*
hsa-miR-106a hsa-miR-489 hsa-miR-519c-
3p
hsa-miR-106b hsa-miR-498 hsa-miR-520f
hsa-miR-140a hsa-miR-
517a
hsa-miR-520g
hsa-miR-182 hsa-miR-
517b
hsa-miR-520h
hsa-miR-183 hsa-miR-638 hsa-miR-525-5p
hsa-miR-187 hsa-miR-663 hsa-miR-629
hsa-miR-200c hsa-miR-923

Table 2.

miR-290/302 seed region family

miRNAs 5’-3’ guide strand sequence#
miR-290 cluster
mmu-miR-290-3p aaagugccgccuaguuuuaagccc
mmu-miR-291a-3p aaagugcuuccacuuugugugc
mmu-miR-292-3p aaagugccgccagguuuugagugu
mmu-miR-291b-3p aaagugcauccauuuuguuugu
mmu-miR-294-3p aaagugcuucccuuuugugugu
mmu-miR-295-3p aaagugcuacuacuuuugagucu
miR-302b cluster
mmu-miR-302b-3p uaagugcuuccauguuuuaguag
mmu-miR-302c-3p aagugcuuccauguuucagugg
mmu-miR-302a-3p uaagugcuuccauguuuugguga
mmu-miR-302d-3p uaagugcuuccauguuugagugu
miR-17 cluster
mmu-miR-17-5p caaagugcuuacagugcagguag
mmu-miR-20a-5p uaaagugcuuauagugcagguag
miR-106b cluster
mmu-miR-106b-5p uaaagugcugacagugcagau
mmu-miR-93-5p caaagugcuguucgugcagguag
miR-106a cluster
mmu-miR-106a caaagugcuaacagugcagguag
mmu-miR-20b caaagugcucauagugcagguag
miR-130/301/721 family
mmu-miR-130a cagugcaauguuaaaagggcau
mmu-miR-130b cagugcaaugaugaaagggcau
mmu-miR-301a cagugcaauaguauugucaaagc
mmu-miR-301b cagugcaaugguauugucaaagc
mmu-miR-721 cagugcaauuaaaagggggaa
#

Bold and enlarge nucleotides represent conserved regions

During MET stage of OSKM-induced reprogramming, aggregates and colonies of reprogrammed cells become visible under low magnification microscopy as reprogrammed cells acquire epithelial cell features. These cells begin to express pluripotency markers, of which SSEA-1 is the earliest surface marker to indicate the potential iPS cells17, 18. As the reprogrammed cells move towards a state of pluripotency, Nanog, Esrrb, Lin28, Dppa4, Tert, Sox2, and Oct-4 are endogenously expressed, demonstrating that the core circuit of pluripotency has been established17-19, 70. The embryonic stem cell cell-cycle-regulating (ESCC) miRNAs, the miR-302 clusters (Figure 1), are also expressed during the transition stage day 4 to day 7 post induced reprogramming34, 126, mainly induced by the reprogramming factor c-Myc31, 37. Recent study has shown that the promoter of miR-302 cluster can be bound and that the expression of miR-302 can be induced by vitamin C-dependent Oct4/Jhdm1b cooperation during reprogramming127. The biogenesis of miRNAs has been shown to be critical to efficient reprogramming, because Ago2 downregulation reduces the number of iPSC colonies34. Depletion of the miR-302 family reduces reprogramming efficiency in response to OSK or OSKM31, 127, suggesting that the miR-302 family plays essential roles in the reprogramming process. Ectopic expression of the miR-290 or miR-302 clusters has been shown to improve OSKM- or OSK-reprogramming36, 37 by promoting MET through inhibition of the TGF-□ receptor31, 34, 36. Recent finding128 also demonstrated that miR-290 cluster maintain pluripotency by repressing nuclear factor kappa B (NF-□B) signaling pathway, which in turn restricts epithelial to mesenchymal transition in ES cells. Furthermore, the miR-290/302 seed family targets diverse functional groups to positively enhance induced reprogramming, including cell cycle regulation, (Cdkn1a, Rbl2, and Cdc2l6) and epigenetic regulation (Aof1, Aof2, Mecp1-p66, MECP2, Mbd2, and Smarcc2)13, 36.

Other miRNAs have been identified to enhance reprogramming. For example, miR-17/92, miR-106b/25, and miR-106a/363 clusters boost reprogramming by targeting Tgfbr2 and p2134. Notably, miR-17, miR-93, and miR-106a have also been induced during the MET stage (day 4 post reprogramming)34, 49. Moreover, introduction of miR-106b and miR-93 miRNA mimics can promote MET (Figure 1) to boost reprogramming efficiency34. The miR-130/301/721 family (Figure 1), identified by miRNA screening, target the homeobox transcription factor Meox2 (also known as Gax) to achieve ~2-fold increase in reprogramming35. All those miRNAs (miR-17, 106a, 106b clusters, and miR-130/301/721 family) share a similar seed region with the miR-290/302 family (Table 2), suggesting that an abundance of miRNAs containing the miR-290/302 seed region play significant roles in various biological functions and intrinsically act as positive regulator to reprogramming.

The miR-290/302 seed family plays multiple roles at the ES stage121 and during the reprogramming process, and the miR-290 and miR-302 clusters are the predominant miRNA population expressed in mammalian ES cells. Therefore, the miR-290/302 seed family may have the potential to induce somatic cell reprogramming in the absence of transgenes OSKM. The reprogramming potential of the miR-302 cluster was first tested in human cancer cells, which showed that the signature properties of pluripotent stem cells are acquired in miR-iPSCs14. Following this finding, several reports demonstrated that the miR-302 cluster could reprogram various primary cell types into pluripotent stem cells13, 15, 16. Among these, Anokye-Danso et al. demonstrated that miRNA-mediated reprogramming is more efficient than transcription factor-mediated method in both mouse (81.5% versus 17.9%) and human somatic cells (10% versus 0.004%)15. But to achieve this striking efficiency, suppression or low level of Hdac2 seems to be required in both mouse and human cells15, 16. Miyoshi et al. further demonstrated that clinically-applicable iPS cells can be generated by introducing only a group of mature miRNAs (miR-200c, miR-302 family, and miR-369s), without retro-viral integration in genome16. However, this transfection-base reprogramming can only reach 0.01% reprogramming efficiency in mouse cells, and even lower (0.001%) in human cells16. The methodology of administrating miRNAs may be one of the main reasons to cause the difference in miR-induced reprogramming efficiency between these two reports, Anokye-Danso et al. (virus transduction)15 and Miyoshi et al. (small RNA transfection)16. In addition, distinct combinations of miRNAs were employed for reprogramming process: miR-302 cluster combined with valproic acid (VPA) treatment vs miR-200c, miR-302abcd, and miR-369s. Interestingly, VPA for Hdac2 suppression and miR-367 are required in viral transduction method, but both are dispensable in miR transfection method. These protocol variations may need to be vigorously tested to further improve the efficiency of reprogramming and clinical applicability of iPS cells. Despite the phenomenon of miR-induced somatic reprograming, how microRNAs can perturb somatic molecular networks and then launch pluripotent regulatory networks remains unknown15, 16.

The mechanisms of miRNA-only reprogramming

As described above, numerous miR-290/302 seed family targets have been identified, but these molecular networks have only been shown in the ES cell context or with forced expression of reprogramming factors OSKM. Previous studies showed that the miR-302 cluster reactivates Oct4 and Nanog through releasing epigenetic repression on the promoter regions by targeting lysine-specific histone demethylases 1 and 2 (AOF1/2), which regulate histone lysine 3 methylation level, and also by targeting methyl-CpG binding proteins 1 and 2 (MECP1/2), which coordinate with DNMT1-mediated gene regulations13. However, Subramanyam et al. showed that only Tgfb2r was detectably changed under the same miR-only reprogramming conditions36. A change in expression of MECP2 and other known targets of miR-302 could only be detected in the presence of three or four reprogramming factors36, suggesting that the reprogramming effect of miR-302 is due to modulating regulatory networks in a cell context-dependent manner. Therefore, the miR-302 cluster may exert its reprogramming potential through distinct routes from those of Yamanaka’s factors, but can induce reprogrammed cells to eventually reach a similar, if not identical, stage of pluripotency.

Can miRNAs bring us toward the next level of regenerative medicine?

Creating iPS cells by using miRNAs represent a great advance in stem cell biology and regenerative medicine. Inspired by induced reprogramming technology, numerous laboratories have shown that forced expression of specific transcription factors can also transform one cell type to the desired one129-132. In near future, we may be able to alter the cell identities with high efficiency by transiently introduction of tissue-specific miRNAs only. Since miRNAs can be easily introduced into a variety of cell types by transfection similar to siRNAs, using only mature miRNAs without viral integration can significantly reduce the technical requirement. Oncogene introduction and genomic integration of transgenes can also be eliminated, because transfected miRNAs are transiently expressed in cells with specific half-lives. With efficiency of two orders of magnitude increase relative to OSKM-induced reprogramming15, utilizing miRNAs provides the best way to date to induce pluripotent stem cells. Despite the great advance of reprogramming technologies, we are only about to understand the molecular basis underneath the reprogramming process. It could be challenging to decipher the molecular regulations in miRNA-mediated reprogramming because miRNAs usually target a large number of genes to modulate biological networks. New high throughput RNA capturing and sequencing technologies may assist in identifying miRNA targets and their roles in reprogramming 133, 134.

Given the reprogramming process takes place in a stochastic manner, it is likely that only part of modulating forces from each reprogramming factor affect positively toward inducing pluripotency. Upon introduction of four reprogramming factors into somatic cells, transcriptional networks are disturbed by forced-expressed transcription factors. On the other hands, those factors bind and regulate hundreds of targets to rebuild distinct networks. The types of reconstructed transcriptional networks are possibly decided by what combinations are from the contribution of each reprogramming factor. Since pluripotency is the only expected phenotype, most of the reprogrammed cell types fail and only a few cells working a way out of this chaos to reach the end point, bearing ES-like transcriptome. And since it is a random event upon induced reprogramming, it is unlikely to only have a single and well-defined molecular transition under the coordination of four reprogramming factors, which may vary cell to cell. Secondary tet-inducible reprogramming system may serve this purpose better to shed light on the transcriptome transitions, because the defined dosage of reprogramming factors135 may reduce the noise compared with random combinations of OSKM. miRNAs may serve as another tools to decipher the cloud of reprogramming process, since the targets of miRNAs are directed by seed region sequences. However, the progression of miR-induced reprogramming is unknown and the molecular transitions are likely distinct from the ones induced with OSKM, while critical molecular signatures may still conserve. Furthermore, extensive examinations are required to establish standard protocols to create miR-induced pluripotent stem cells, since several discrepancies on miRNA combinations, administering methods, and reprogramming efficiency need to be clarified. Therefore, step-wise dissection of miR-induced reprogramming is required to elucidate the critical features, which are involved in both transcriptional factor-induced and miRNA-induced reprogramming.

Acknowledgements

We are grateful to members of the Rana laboratory for helpful discussions. This work was supported in part by grants from the National Institutes of Health to T.M.R.

BIOGRAPHICAL INFORMATION

Chao-Shun Yang received his Master degree in Department of Biochemistry in 2000 from National Cheng Kung University, Taiwan. He is currently a Ph.D student at University of Massachusetts Medical School and is completing his research dissertation in Dr.Tariq Rana’s laboratory at Sanford-Burnham Medical Research Institute, La Jolla, California.

Tariq M. Rana received his Ph.D from the University of California at Davis and was an American Cancer Society fellow at the University of California at Berkeley. He was a Professor of Biochemistry and Molecular Pharmacology and Director of Program in Chemical Biology at the University of Massachusetts Medical School before joining the Sanford-Burnham Medical Research Institute in 2008. He is currently Professor and Director of the RNA Biology Program at Sanford-Burnham Medical Research Institute, where his laboratory studies RNA regulation of development and disease.

References

  • 1.Takahashi K, Yamanaka S. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]
  • 2.Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, Thomson JA. Science. 2007;318:1917–1920. doi: 10.1126/science.1151526. [DOI] [PubMed] [Google Scholar]
  • 3.Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. Nature. 2007;448:318–324. doi: 10.1038/nature05944. [DOI] [PubMed] [Google Scholar]
  • 4.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
  • 5.Meissner A, Wernig M, Jaenisch R. Nat Biotechnol. 2007;25:1177–1181. doi: 10.1038/nbt1335. [DOI] [PubMed] [Google Scholar]
  • 6.Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Nature. 2008;451:141–146. doi: 10.1038/nature06534. [DOI] [PubMed] [Google Scholar]
  • 7.Yamanaka S. Cell Stem Cell. 2007;1:39–49. doi: 10.1016/j.stem.2007.05.012. [DOI] [PubMed] [Google Scholar]
  • 8.Stadtfeld M, Hochedlinger K. Genes & development. 2010;24:2239–2263. doi: 10.1101/gad.1963910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Plath K, Lowry WE. Nature reviews. Genetics. 2011;12:253–265. doi: 10.1038/nrg2955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ho R, Chronis C, Plath K. Journal of cellular physiology. 2011;226:868–878. doi: 10.1002/jcp.22450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hochedlinger K, Plath K. Development. 2009;136:509–523. doi: 10.1242/dev.020867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ. Cell Stem Cell. 2010;7:618–630. doi: 10.1016/j.stem.2010.08.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Nucleic Acids Res. 2011;39:1054–1065. doi: 10.1093/nar/gkq850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY. Rna. 2008;14:2115–2124. doi: 10.1261/rna.1162708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, Zhang Y, Yang W, Gruber PJ, Epstein JA, Morrisey EE. Cell Stem Cell. 2011;8:376–388. doi: 10.1016/j.stem.2011.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Cell Stem Cell. 2011;8:633–638. doi: 10.1016/j.stem.2011.05.001. [DOI] [PubMed] [Google Scholar]
  • 17.Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Cell Stem Cell. 2008;2:230–240. doi: 10.1016/j.stem.2008.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H, Jaenisch R. Cell Stem Cell. 2008;2:151–159. doi: 10.1016/j.stem.2008.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sridharan R, Tchieu J, Mason MJ, Yachechko R, Kuoy E, Horvath S, Zhou Q, Plath K. Cell. 2009;136:364–377. doi: 10.1016/j.cell.2009.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yang CS, Lopez CG, Rana TM. Stem Cells. 2011;29:1528–1536. doi: 10.1002/stem.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Nature. 2009;460:1132–1135. doi: 10.1038/nature08235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M. Nature. 2009;460:1136–1139. doi: 10.1038/nature08290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. Nature. 2009;460:1149–1153. doi: 10.1038/nature08287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisua Belmonte JC. Nature. 2009;460:1140–1144. doi: 10.1038/nature08311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J. Genes & development. 2009;23:2134–2139. doi: 10.1101/gad.1811609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Nature. 2009;460:1145–1148. doi: 10.1038/nature08285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K. Cell Stem Cell. 2009;5:491–503. doi: 10.1016/j.stem.2009.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Maherali N, Hochedlinger K. Curr Biol. 2009;19:1718–1723. doi: 10.1016/j.cub.2009.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yang CS, Li Z, Rana TM. Rna. 2011;17:1451–1460. doi: 10.1261/rna.2664111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lipchina I, Elkabetz Y, Hafner M, Sheridan R, Mihailovic A, Tuschl T, Sander C, Studer L, Betel D. Genes & development. 2011;25:2173–2186. doi: 10.1101/gad.17221311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liao B, Bao X, Liu L, Feng S, Zovoilis A, Liu W, Xue Y, Cai J, Guo X, Qin B, Zhang R, Wu J, Lai L, Teng M, Niu L, Zhang B, Esteban MA, Pei D. J Biol Chem. 2011;286:17359–17364. doi: 10.1074/jbc.C111.235960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Melton C, Judson RL, Blelloch R. Nature. 2010;463:621–626. doi: 10.1038/nature08725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lin SL, Chang DC, Ying SY, Leu D, Wu DT. Cancer Res. 2010;70:9473–9482. doi: 10.1158/0008-5472.CAN-10-2746. [DOI] [PubMed] [Google Scholar]
  • 34.Li Z, Yang CS, Nakashima K, Rana TM. Embo J. 2011;30:823–834. doi: 10.1038/emboj.2011.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pfaff N, Fiedler J, Holzmann A, Schambach A, Moritz T, Cantz T, Thum T. EMBO Rep. 2011;12:1153–1159. doi: 10.1038/embor.2011.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, Blelloch R. Nature biotechnology. 2011;29:443–448. doi: 10.1038/nbt.1862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Judson RL, Babiarz JE, Venere M, Blelloch R. Nature biotechnology. 2009;27:459–461. doi: 10.1038/nbt.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Cao H, Yang CS, Rana TM. PLoS One. 2008;3:e2820. doi: 10.1371/journal.pone.0002820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rana TM. Nat Rev Mol Cell Biol. 2007;8:23–36. doi: 10.1038/nrm2085. [DOI] [PubMed] [Google Scholar]
  • 40.Li Z, Rana TM. Acc Chem Res. 2012;45:1122–1131. doi: 10.1021/ar200253u. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ambros V. Curr Opin Genet Dev. 2011;21:511–517. doi: 10.1016/j.gde.2011.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Tiscornia G, Izpisua Belmonte JC. Genes & development. 2010;24:2732–2741. doi: 10.1101/gad.1982910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Subramanyam D, Blelloch R. Curr Opin Genet Dev. 2011;21:498–503. doi: 10.1016/j.gde.2011.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kim M, Kasinski AL, Slack FJ. Lancet Oncol. 2011;12:319–321. doi: 10.1016/S1470-2045(11)70067-5. [DOI] [PubMed] [Google Scholar]
  • 45.Kasinski AL, Slack FJ. Curr Opin Mol Ther. 2010;12:147–157. [PubMed] [Google Scholar]
  • 46.Esteller M. Nature reviews. Genetics. 2011;12:861–874. doi: 10.1038/nrg3074. [DOI] [PubMed] [Google Scholar]
  • 47.Farazi TA, Spitzer JI, Morozov P, Tuschl T. J Pathol. 2011;223:102–115. doi: 10.1002/path.2806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.van Kouwenhove M, Kedde M, Agami R. Nat Rev Cancer. 2011;11:644–656. doi: 10.1038/nrc3107. [DOI] [PubMed] [Google Scholar]
  • 49.Chen J, Wang G, Lu C, Guo X, Hong W, Kang J, Wang J. PLoS One. 2012;7:e40849. doi: 10.1371/journal.pone.0040849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hanna JH, Saha K, Jaenisch R. Cell. 2010;143:508–525. doi: 10.1016/j.cell.2010.10.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Orkin SH, Hochedlinger K. Cell. 2011;145:835–850. doi: 10.1016/j.cell.2011.05.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Lai MI, Wendy-Yeo WY, Ramasamy R, Nordin N, Rosli R, Veerakumarasivam A, Abdullah S. J Assist Reprod Genet. 2011;28:291–301. doi: 10.1007/s10815-011-9552-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Han JW, Yoon YS. Antioxid Redox Signal. 2012;17:205–223. doi: 10.1089/ars.2011.4375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Gonzalez F, Boue S, Izpisua Belmonte JC. Nature reviews. Genetics. 2011;12:231–242. doi: 10.1038/nrg2937. [DOI] [PubMed] [Google Scholar]
  • 55.Tiscornia G, Vivas EL, Izpisua Belmonte JC. Nat Med. 2011;17:1570–1576. doi: 10.1038/nm.2504. [DOI] [PubMed] [Google Scholar]
  • 56.Robinton DA, Daley GQ. Nature. 2012;481:295–305. doi: 10.1038/nature10761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Grskovic M, Javaherian A, Strulovici B, Daley GQ. Nat Rev Drug Discov. 2011;10:915–929. doi: 10.1038/nrd3577. [DOI] [PubMed] [Google Scholar]
  • 58.Lipchina I, Studer L, Betel D. Cell Cycle. 2012;11:1517–1523. doi: 10.4161/cc.19846. [DOI] [PubMed] [Google Scholar]
  • 59.Mallanna SK, Rizzino A. Dev Biol. 2010;344:16–25. doi: 10.1016/j.ydbio.2010.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Kuo CH, Deng JH, Deng Q, Ying SY. Biochemical and biophysical research communications. 2012;417:11–16. doi: 10.1016/j.bbrc.2011.11.058. [DOI] [PubMed] [Google Scholar]
  • 61.Wang Y, Blelloch R. Results Probl Cell Differ. 2011;53:459–472. doi: 10.1007/978-3-642-19065-0_19. [DOI] [PubMed] [Google Scholar]
  • 62.Heinrich EM, Dimmeler S. Circulation research. 2012;110:1014–1022. doi: 10.1161/CIRCRESAHA.111.243394. [DOI] [PubMed] [Google Scholar]
  • 63.Li MA, He L. Bioessays. 2012;34:670–680. doi: 10.1002/bies.201200019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pfaff N, Moritz T, Thum T, Cantz T. J Mol Med (Berl) 2012;90:747–752. doi: 10.1007/s00109-012-0922-z. [DOI] [PubMed] [Google Scholar]
  • 65.Yamanaka S. Nature. 2009;460:49–52. doi: 10.1038/nature08180. [DOI] [PubMed] [Google Scholar]
  • 66.Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R. Nature. 2009;462:595–601. doi: 10.1038/nature08592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.MacArthur BD, Please CP, Oreffo RO. PLoS One. 2008;3:e3086. doi: 10.1371/journal.pone.0003086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A, Bernstein BE, Meissner A. Cell Stem Cell. 2011;8:96–105. doi: 10.1016/j.stem.2010.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Li R, Liang J, Ni S, Zhou T, Qing X, Li H, He W, Chen J, Li F, Zhuang Q, Qin B, Xu J, Li W, Yang J, Gan Y, Qin D, Feng S, Song H, Yang D, Zhang B, Zeng L, Lai L, Esteban MA, Pei D. Cell Stem Cell. 2010;7:51–63. doi: 10.1016/j.stem.2010.04.014. [DOI] [PubMed] [Google Scholar]
  • 70.Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, Woltjen K, Nagy A, Wrana JL. Cell Stem Cell. 2010;7:64–77. doi: 10.1016/j.stem.2010.04.015. [DOI] [PubMed] [Google Scholar]
  • 71.Wanzel M, Herold S, Eilers M. Trends Cell Biol. 2003;13:146–150. doi: 10.1016/s0962-8924(03)00003-5. [DOI] [PubMed] [Google Scholar]
  • 72.Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. Nat Genet. 2008;40:43–50. doi: 10.1038/ng.2007.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Lotterman CD, Kent OA, Mendell JT. Cell Cycle. 2008;7:2493–2499. doi: 10.4161/cc.7.16.6452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV. Nature. 2009;458:762–765. doi: 10.1038/nature07823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, Jung J, Gao P, Dang CV, Beer MA, Thomas-Tikhonenko A, Mendell JT. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:3384–3389. doi: 10.1073/pnas.0808300106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Lin CH, Lin C, Tanaka H, Fero ML, Eisenman RN. PLoS One. 2009;4:e7839. doi: 10.1371/journal.pone.0007839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Lin CH, Jackson AL, Guo J, Linsley PS, Eisenman RN. Embo J. 2009;28:3157–3170. doi: 10.1038/emboj.2009.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Smith K, Dalton S. Regen Med. 2010;5:947–959. doi: 10.2217/rme.10.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Smith KN, Singh AM, Dalton S. Cell Stem Cell. 2010;7:343–354. doi: 10.1016/j.stem.2010.06.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME. J Cell Biochem. 2010;110:1155–1164. doi: 10.1002/jcb.22630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. The Journal of experimental medicine. 2010;207:1589–1597. doi: 10.1084/jem.20100035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. Nature. 2008;456:980–984. doi: 10.1038/nature07511. [DOI] [PubMed] [Google Scholar]
  • 83.Yang J, van Oosten AL, Theunissen TW, Guo G, Silva JC, Smith A. Cell Stem Cell. 2010;7:319–328. doi: 10.1016/j.stem.2010.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Wray J, Kalkan T, Smith AG. Biochem Soc Trans. 2010;38:1027–1032. doi: 10.1042/BST0381027. [DOI] [PubMed] [Google Scholar]
  • 85.Nichols J, Silva J, Roode M, Smith A. Development. 2009;136:3215–3222. doi: 10.1242/dev.038893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A. Nature. 2008;453:519–523. doi: 10.1038/nature06968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Park SY, Lee JH, Ha M, Nam JW, Kim VN. Nat Struct Mol Biol. 2009;16:23–29. doi: 10.1038/nsmb.1533. [DOI] [PubMed] [Google Scholar]
  • 88.Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. Genes & development. 2009;23:1743–1748. doi: 10.1101/gad.1812509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG. Nat Cell Biol. 2008;10:987–993. doi: 10.1038/ncb1759. [DOI] [PubMed] [Google Scholar]
  • 90.Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. Cancer Res. 2007;67:9762–9770. doi: 10.1158/0008-5472.CAN-07-2462. [DOI] [PubMed] [Google Scholar]
  • 91.Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. Cell Cycle. 2007;6:2585–2590. doi: 10.4161/cc.6.21.4845. [DOI] [PubMed] [Google Scholar]
  • 92.He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. Nature. 2007;447:1130–1134. doi: 10.1038/nature05939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Mol Cell. 2007;26:731–743. doi: 10.1016/j.molcel.2007.05.017. [DOI] [PubMed] [Google Scholar]
  • 94.Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Mol Cell. 2007;26:745–752. doi: 10.1016/j.molcel.2007.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks GG, Hannon GJ, He L. Nat Cell Biol. 2011;13:1353–1360. doi: 10.1038/ncb2366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP, Kyba M, Barton MC. PLoS Biol. 2012;10:e1001268. doi: 10.1371/journal.pbio.1001268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, Hermeking H. Cell Cycle. 2011;10:4256–4271. doi: 10.4161/cc.10.24.18552. [DOI] [PubMed] [Google Scholar]
  • 98.Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ, Yook JI. J Cell Biol. 2011;195:417–433. doi: 10.1083/jcb.201103097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. Cell. 2009;137:647–658. doi: 10.1016/j.cell.2009.02.038. [DOI] [PubMed] [Google Scholar]
  • 100.Liu T, Cheng W, Huang Y, Huang Q, Jiang L, Guo L. Exp Cell Res. 2012;318:424–434. doi: 10.1016/j.yexcr.2011.12.004. [DOI] [PubMed] [Google Scholar]
  • 101.Ma L, Teruya-Feldstein J, Weinberg RA. Nature. 2007;449:682–688. doi: 10.1038/nature06174. [DOI] [PubMed] [Google Scholar]
  • 102.Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. Mol Cell Biol. 2008;28:6773–6784. doi: 10.1128/MCB.00941-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. Nat Cell Biol. 2008;10:593–601. doi: 10.1038/ncb1722. [DOI] [PubMed] [Google Scholar]
  • 104.Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, Brown AJ, Lutze-Mann LH. Int J Cancer. 2010;126:28–40. doi: 10.1002/ijc.24813. [DOI] [PubMed] [Google Scholar]
  • 105.Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. EMBO Rep. 2008;9:582–589. doi: 10.1038/embor.2008.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. Nat Cell Biol. 2009;11:1487–1495. doi: 10.1038/ncb1998. [DOI] [PubMed] [Google Scholar]
  • 107.Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Gynecol Oncol. 2011;121:200–205. doi: 10.1016/j.ygyno.2010.12.339. [DOI] [PubMed] [Google Scholar]
  • 108.Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA. Nature biotechnology. 2010;28:341–347. doi: 10.1038/nbt.1618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Wang HR, Zhang Y, Ozdamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, Wrana JL. Science. 2003;302:1775–1779. doi: 10.1126/science.1090772. [DOI] [PubMed] [Google Scholar]
  • 110.Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, Mu J, Zhang L, Miller D, Grizzle W, Zhang HG. Oncogene. 2011;30:3440–3453. doi: 10.1038/onc.2011.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Gregory PA, Bracken CP, Bert AG, Goodall GJ. Cell Cycle. 2008;7:3112–3118. doi: 10.4161/cc.7.20.6851. [DOI] [PubMed] [Google Scholar]
  • 112.Wiklund ED, Kjems J, Clark SJ. Epigenomics. 2010;2:823–840. doi: 10.2217/epi.10.51. [DOI] [PubMed] [Google Scholar]
  • 113.Park SM, Gaur AB, Lengyel E, Peter ME. Genes & development. 2008;22:894–907. doi: 10.1101/gad.1640608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Chen J, Liu J, Yang J, Chen Y, Ni S, Song H, Zeng L, Ding K, Pei D. Cell research. 2011;21:205–212. doi: 10.1038/cr.2010.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Nat Genet. 2008;40:1478–1483. doi: 10.1038/ng.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K. Genes & development. 2005;19:489–501. doi: 10.1101/gad.1248505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:12135–12140. doi: 10.1073/pnas.0505479102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Houbaviy HB, Murray MF, A. Sharp P. Dev Cell. 2003;5:351–358. doi: 10.1016/s1534-5807(03)00227-2. [DOI] [PubMed] [Google Scholar]
  • 119.Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN, Kim KS. Dev Biol. 2004;270:488–498. doi: 10.1016/j.ydbio.2004.02.019. [DOI] [PubMed] [Google Scholar]
  • 120.Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. Cell. 2007;129:1401–1414. doi: 10.1016/j.cell.2007.04.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. Cell. 2008;134:521–533. doi: 10.1016/j.cell.2008.07.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, Archer TK. Mol Cell Biol. 2008;28:6426–6438. doi: 10.1128/MCB.00359-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Rosa A, Spagnoli FM, Brivanlou AH. Dev Cell. 2009;16:517–527. doi: 10.1016/j.devcel.2009.02.007. [DOI] [PubMed] [Google Scholar]
  • 124.Benetti R, Gonzalo S, Jaco I, Munoz P, Gonzalez S, Schoeftner S, Murchison E, Andl T, Chen T, Klatt P, Li E, Serrano M, Millar S, Hannon G, Blasco MA. Nat Struct Mol Biol. 2008;15:268–279. doi: 10.1038/nsmb.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Sinkkonen L, Hugenschmidt T, Berninger P, Gaidatzis D, Mohn F, Artus-Revel CG, Zavolan M, Svoboda P, Filipowicz W. Nat Struct Mol Biol. 2008;15:259–267. doi: 10.1038/nsmb.1391. [DOI] [PubMed] [Google Scholar]
  • 126.Kamata M, Liang M, Liu S, Nagaoka Y, Chen IS. PLoS One. 2010;5:e11834. doi: 10.1371/journal.pone.0011834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, Qin B, Zeng L, Esteban MA, Pan G, Pei D. Cell Stem Cell. 2011;9:575–587. doi: 10.1016/j.stem.2011.10.005. [DOI] [PubMed] [Google Scholar]
  • 128.Luningschror P, Stocker B, Kaltschmidt B, Kaltschmidt C. Stem Cells. 2012;30:655–664. doi: 10.1002/stem.1033. [DOI] [PubMed] [Google Scholar]
  • 129.Ambasudhan R, Talantova M, Coleman R, Yuan X, Zhu S, Lipton SA, Ding S. Cell Stem Cell. 2011;9:113–118. doi: 10.1016/j.stem.2011.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, Lee-Messer C, Dolmetsch RE, Tsien RW, Crabtree GR. Nature. 2011;476:228–231. doi: 10.1038/nature10323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Jopling C, Boue S, Izpisua Belmonte JC. Nat Rev Mol Cell Biol. 2011;12:79–89. doi: 10.1038/nrm3043. [DOI] [PubMed] [Google Scholar]
  • 132.Chambers SM, Studer L. Cell. 2011;145:827–830. doi: 10.1016/j.cell.2011.05.036. [DOI] [PubMed] [Google Scholar]
  • 133.Baigude H, Ahsanullah, Li Z, Zhou Y, Rana TM. Angew Chem Int Ed Engl. 2012;51:5880–5883. doi: 10.1002/anie.201201512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Zhou H, Arcila ML, Li Z, Lee EJ, Henzler C, Liu J, Rana TM, Kosik KS. Nucleic Acids Res. 2012;40:5864–5875. doi: 10.1093/nar/gks247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Markoulaki S, Hanna J, Beard C, Carey BW, Cheng AW, Lengner CJ, Dausman JA, Fu D, Gao Q, Wu S, Cassady JP, Jaenisch R. Nature biotechnology. 2009;27:169–171. doi: 10.1038/nbt.1520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Wilson KD, Venkatasubrahmanyam S, Jia F, Sun N, Butte AJ, Wu JC. Stem cells and development. 2009;18:749–758. doi: 10.1089/scd.2008.0247. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES